Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences Applications in Pharmaceutical Analysis and Forced Degradation Studies (Hall 2)

Mandar Kulkarni's Biography



Mandar Kulkarni, Chief Technology Officer, Bioserve Biotechnologies

Dr Mandar Kulkarni joined CGI with over five years of experience in both clinical and genomic development and will be focused initially on three key strategic areas. Dr. Kulkarni’s initiatives include enhancing and accelerating the Company’s efforts in offering next-generation sequencing (NGS) based tests to leading research institutions, clinical partners and biopharma companies and strengthening CG India’s partnerships with cancer centers, and hospitals. Dr. Kulkarni will also spearhead the development of an oncology-focused knowledge base that will include genomic information geared toward facilitating the personalization of treatment for Indian populations. The database will also be used to inform and accelerate discovery and clinical development. Prior to joining CG India, Kulkarni was Head of molecular biology and genomics at Sandor Lifesciences, where his team designed and executed next-generation sequencing, bioinformatics, and microarray initiatives. Kulkarni was also a senior scientist at M/Z Diagnostics where he developed and clinically validated a diagnostic assay for rapid detection of multi-drug resistant bacterial infections. Dr. Kulkarni received his Bachelor of Science degree from Pune University and the University of Wisconsin and earned a doctorate degree from Purdue University. He completed his postdoctoral training at Yale School of Medicine.

Mandar Kulkarni Image

Use of Mass Spectrometry for Rapid Detection of Carbapenem Resistant Gram Negative Hospital Acquired Infections

Friday, 20 November 2015 at 15:00

Add to Calendar ▼2015-11-20 15:00:002015-11-20 16:00:00Europe/LondonUse of Mass Spectrometry for Rapid Detection of Carbapenem Resistant Gram Negative Hospital Acquired Infections SELECTBIOenquiries@selectbiosciences.com

This talk will discuss the use of mass spectrometry to detect carbapenemase activity, by selectively monitoring for the appearance of carbapenem hydrolysis products in critical patient specimens: positive blood cultures and urine sample.


Add to Calendar ▼2015-11-20 00:00:002015-11-20 00:00:00Europe/LondonApplications in Pharmaceutical Analysis and Forced Degradation Studies (Hall 2)SELECTBIOenquiries@selectbiosciences.com